Yael Cohen, MD, on the Safety Profile of Cilta-Cel in Refractory Myeloma

Video

Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

In an interview with CancerNetwork®, Yael Cohen, MD, a senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed the safety profile of ciltacabtagene autoleucel in a population of patients with lenalidomide (Revlimid)–refractory multiple myeloma.

She highlighted that the safety of the CAR T-cell therapy was encouraging, with no new safety findings reading out in the phase 2 CARTITUDE-2 trial (NCT04133636).

Transcript:

The safety was certainly manageable. There were no new adverse effects that came out. Specifically, in the earlier parts of the development, there were some concerns about the movement and neurocognitive changes and there was a mitigation program that was put in place. Since then, the rate, when tested, went down. In this study, in particular, there were no cases. Over 200 patients were dosed in the overall program and the rate went down to 0.5%. That [was] also encouraging.

Reference

Cohen YC, Cohen AD, Delforge M, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Presented at: 2021 ASH Annual Meeting; December 11-13, 2021; Atlanta, GA. Poster 3866.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Related Content